Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
View original at finance.yahoo.comProthena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Partnered programs have the potential to earn up to approximately $3 billion in future aggregate milestones in addition to potential future royalties
80% confidencePrasinezumab has peak sales potential greater than $3.5 billion (unadjusted) and could be the first disease-modifying treatment for Parkinson's disease
80% confidenceExpected to end 2026 with approximately $255 million in cash (midpoint)
80% confidenceEstimated full year 2026 net loss of $67 to $72 million, including estimated $24 million of non-cash share-based compensation expense
80% confidencePotential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026
80% confidenceExpect to share more data from preclinical programs later this year (2026)
80% confidenceFull year 2026 net cash used in operating and investing activities expected to be $50 to $55 million
80% confidencePRX012 patients on 400 mg dose for 18 months reached mean centiloid level of ~16.0 CL with 9 of 12 achieving amyloid negativity, but robust plaque clearance was associated with non-competitive rates of ARIA-E
80% confidence